Patients with recurrent, platinum-sensitive epithelial ovarian cancer (defined as disease relapse ≥6 months after first-line platinum-based chemotherapy) typically receive additional platinum-based regimens with or without bevacizumab, although most patients will have further relapse events. Now, data from one of the arms of the phase Ib FORWARD II trial show that the addition of the antibody–drug conjugate mirvetuximab soravtansine to carboplatin and bevacizumab has promising activity in patients with folate-receptor-α-positive (FRα+) disease.

A total of 41 women received triplet therapy. FRα positivity was defined as a score of ≥2 + in ≥50% of tumour cells as determined with the VENTANA FOLR1 RxDx immunohistochemistry assay; 49% and 51% of patients had FRα tumour expression levels ≥75% and 50–74%, respectively. Objective response rate (ORR) and safety were the co-primary end points.